Detalles de la búsqueda
1.
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.
Drug Resist Updat
; 68: 100947, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36812747
2.
Elevated Sera IL-6 and NK-T Cells Associated With Increased Pathological Complete Response in HER2-positive Breast Cancer With Carboplatin-based Neoadjuvant Therapy.
Altern Ther Health Med
; 29(3): 246-253, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36881538
3.
Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast.
Breast J
; 20(2): 166-73, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24400866
4.
[Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
Zhonghua Zhong Liu Za Zhi
; 35(5): 372-6, 2013 May.
Artículo
en Zh
| MEDLINE | ID: mdl-24054015
5.
Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment.
Medicine (Baltimore)
; 102(39): e34903, 2023 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37773875
6.
[Mammographic and pathological features of triple-negative breast cancer].
Zhonghua Zhong Liu Za Zhi
; 34(4): 291-5, 2012 Apr.
Artículo
en Zh
| MEDLINE | ID: mdl-22781043
7.
Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer.
Medicine (Baltimore)
; 101(40): e30892, 2022 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36221359
Resultados
1 -
7
de 7
1
Próxima >
>>